Winner of the Nuclear Medicine 2021 to Receive 25,000 Euros
The Skolkovo Foundation (VEB.RF Group), Bayer company, and Rosatom Healthcare launched the “Nuclear Medicine 2021: best project in the field of radionuclide medicine” competition. Applications are being accepted until 13 October at nuclear.medicine@sk.ru.
The competition organizers are looking for promising innovative projects that are developing radiopharmaceuticals for oncological therapy or other diseases; they are also looking for methods of targeted delivery of and/or retaining therapeutic radionuclides and chelating agents for binding radionuclides. The winner of the Nuclear Medicine competition will receive international, expert consulting support in the form of a science-research accelerator, “KoLaborator,” including a 25,000 euro grant from Bayer company.
Natalia Polushkina, vice president and deputy director of the Skolkovo Foundation biomedical technologies cluster: “It is the second year that Skolkovo is jointly running the Nuclear Medicine competition with its partners. But this time, the list of areas has expanded. Apart from therapeutic radiopharmaceutical developers, there are teams creating methods of targeted radionuclide delivery and chelating agents for binding radionuclides. The competition gives each participant – winner or loser – the opportunity to share their know-how with potential partners and gain unique advice from international experts on developing their project.”
Nuclear medicine is taking place in Russia for the third time and the second year in a row at the Skolkovo Foundation. Bayer actively supports projects that aim to find and develop advanced technologies for treating socially critical diseases. In the company’s opinion, nuclear medicine is a field that is developing dynamically in Russia and has great scientific potential.
Niels Hessmann, CEO of Bayer, general representative for Bayer in Russia and the CIS: “Russia has significant potential in the field of nuclear medicine, including both for high industry expertise as well as the availability of industry resources necessary for development. Despite the numerous positive changes, we see that many opportunities remain untapped. That is precisely why Bayer is already organizing the Nuclear Medicine competition for the third time, within the framework of which we are selecting high-potential projects in the field of radionuclide medicine together with leading Russian and international experts. We at Bayer eagerly look forward to the results of the competition this year, and, following established good tradition, we are ready to work on innovative treatment methods and improving the quality of life and health of people in Russia and the world together with the winner and finalists of the competition.”
Experts from Rosatom Healthcare, the only integrator in radiation technologies for medicine and industry in Rosatom Corporation, are taking part in reviewing the applications. The company is running projects in nuclear medicine, oncologic radiology, and creating equipment and drugs for nuclear and radiological medicine.
Nataliya Komarova, CEO of Rosatom Healthcare: “Rosatom Healthcare is taking part in the Nuclear Medicine competition for the second year, in so far as our division is open for innovative directions in the framework of the company’s development strategy, which includes the development of radiopharmaceutical drugs, equipment for use in nuclear medicine, but also digital solutions. The best company experts will accompany competition participants as mentors for the period duration. Apart from that, the best projects will be awarded the Rosatom Healthcare prize. Our task is to help projects realize their potential in partnership with key market players.”
Applications for “Nuclear Medicine 2021: the best project in the field of radionuclide medicine” are being accepted until 13 October at nuclear.medicine@sk.ru.
Detailed information is available at the competition website: https://nuclearmedicine.sk.ru/.
The competition final takes place at the XXV Russian Oncological Congress on 9 November 2021: https://rosoncoweb.ru/.